DG
David Gaffin
Executive Vice President, Chief Legal Officer, Chief Compliance Officer and Secretary
AlkermesTherapeutic Areas
Alkermes Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Alixorexton (ALKS 2680) | Narcolepsy Type 1 | Phase 3 |
| Sodium Oxybate Extended-Release Oral Suspension | Idiopathic Hypersomnia | Phase 3 |
| Olanzapine and Samidorphan | Schizophrenia and Bipolar I Disorder (Pediatric) | Phase 3 |
Leadership Team at Alkermes
RP
Richard Pops
Chairman and Chief Executive Officer
SC
Sandy Coombs
Senior Vice President, Corporate Affairs and Investor Relations
GD
Grace Doyle
Senior Vice President, Quality
CE
Colleen Ellwanger
Senior Vice President, Program and Project Management Office
AG
Anne Giovanoni
Senior Vice President, Corporate Counsel and Secretary
JH
Jeffrey Harris
Senior Vice President & General Manager, Psychiatry/Addiction Business Unit
TH
Thomas Harvey
Senior Vice President, IT and Chief Information Officer
DJ
Dr. Julie Lekstrom Himes
Senior Vice President, Clinical Development
DC
Dr. Craig Hopkinson
Executive Vice President, Research & Development and Chief Medical Officer
BJ
Blair Jackson
Executive Vice President, Chief Operating Officer